The Strategic Project Council (SPC) of Eurobiomed declares its support to BOYDSense, the MedTech subsidiary of Alpha MOS
Alpha MOS announces that its MedTech subsidiary BOYDSense was auditioned and supported by the CSP of Eurobiomed (Competitiveness Cluster of the South of France, dedicated to the Healthtech) within the framework of an EIC Accelerator application, thus recognizing the excellence of its work of medical innovation.
Health is a strategic sector in Occitanie. The region has a wide range of expertise throughout its territory and includes many institutional players (health institutions, schools, universities, research laboratories, ANITI), as well as many MedTech and Biotech companies and startups. In this very active ecosystem, Eurobiomed plays a key role as a competitiveness cluster in the south of France, dedicated to Healthtech.
Eurobiomed was created in 2009 by all the players in the healthcare sector in the Southern Provence, Alpes Côte d'Azur and Occitanie Pyrenees-Mediterranean regions. This competitiveness cluster brings together an ecosystem of over 400 industrial players, major groups, SMEs and startups, research laboratories and universities, all of whom are involved in accelerating the development of the healthcare sector, from fundamental research to the market, for the benefit of patients and the economy of southern France. The Eurobiomed label is a guarantee of credibility for R&D projects seeking funding. The Strategic Project Council (SPC) certifies R&D projects according to the criteria expected by funders by evaluating, in particular: socio-economic impact, scientific excellence, resources and partnerships, and overall project management.
It is within this framework that BOYDSense has passed the CSP evaluation and has thus obtained a letter of support which is the equivalent of a label for a funding application in France. This news confirms the good dynamics of the company. Indeed, at the end of 2021 BOYDSense has been selected by the European Innovation Council (EIC) Accelerator of the Horizon Europe funding program, recognizing the excellence of its medical innovation work dedicated to the monitoring of chronic diseases. The €2.5M grant from the EIC will accelerate the development of a miniaturized breath analyzer that makes it possible to monitor blood glucose levels in pre-diabetics and type 2 diabetics; as Bruno Thuillier, BOYDSense founder and CTO, confirms: "The Eurobiomed label, added to the recent allocation of European funds through the EIC Accelerator program, are strong testimonials to our vision of developing a revolutionary non-invasive breath analysis device for the monitoring of vital parameters.”